These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 25758902)

  • 1. Poorly differentiated neoplasms of unknown primary site: diagnostic usefulness of a molecular cancer classifier assay.
    Greco FA; Lennington WJ; Spigel DR; Hainsworth JD
    Mol Diagn Ther; 2015 Apr; 19(2):91-7. PubMed ID: 25758902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Renal Cell Carcinoma Presenting as Carcinoma of Unknown Primary Site: Recognition of a Treatable Patient Subset.
    Greco FA; Hainsworth JD
    Clin Genitourin Cancer; 2018 Aug; 16(4):e893-e898. PubMed ID: 29610002
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular profiling diagnosis in unknown primary cancer: accuracy and ability to complement standard pathology.
    Greco FA; Lennington WJ; Spigel DR; Hainsworth JD
    J Natl Cancer Inst; 2013 Jun; 105(11):782-90. PubMed ID: 23641043
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation.
    Varadhachary GR; Talantov D; Raber MN; Meng C; Hess KR; Jatkoe T; Lenzi R; Spigel DR; Wang Y; Greco FA; Abbruzzese JL; Hainsworth JD
    J Clin Oncol; 2008 Sep; 26(27):4442-8. PubMed ID: 18802157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Benefit of Gene Expression Profiling in Gastrointestinal Neuroendocrine Tumors of Unknown Primary Origin.
    Saller JJ; Haider M; Al-Diffalha S; Coppola D
    Anticancer Res; 2022 Mar; 42(3):1381-1396. PubMed ID: 35220231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnosis and management of metastatic neoplasms with unknown primary.
    Bochtler T; Löffler H; Krämer A
    Semin Diagn Pathol; 2018 May; 35(3):199-206. PubMed ID: 29203116
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah Cannon research institute.
    Hainsworth JD; Rubin MS; Spigel DR; Boccia RV; Raby S; Quinn R; Greco FA
    J Clin Oncol; 2013 Jan; 31(2):217-23. PubMed ID: 23032625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene expression profiling in patients with carcinoma of unknown primary site: from translational research to standard of care.
    Hainsworth JD; Greco FA
    Virchows Arch; 2014 Apr; 464(4):393-402. PubMed ID: 24487792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A practical method to determine the site of unknown primary in metastatic neuroendocrine tumors.
    Maxwell JE; Sherman SK; Stashek KM; O'Dorisio TM; Bellizzi AM; Howe JR
    Surgery; 2014 Dec; 156(6):1359-65; discussion 1365-6. PubMed ID: 25456909
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New strategies for carcinoma of unknown primary: the role of tissue-of-origin molecular profiling.
    Varadhachary G
    Clin Cancer Res; 2013 Aug; 19(15):4027-33. PubMed ID: 23519898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular and cytogenetic studies in the diagnosis of patients with poorly differentiated carcinomas of unknown primary site.
    Motzer RJ; Rodriguez E; Reuter VE; Bosl GJ; Mazumdar M; Chaganti RS
    J Clin Oncol; 1995 Jan; 13(1):274-82. PubMed ID: 7799031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Comparing immunohistochemical diagnosis of cancer of unknown primary with gene expression-based tumor classification].
    Morawietz L; Floore A; Stork-Sloots L; Folprecht G; Buettner R; Rieger A; Dietel M; Huebner G
    Pathologe; 2009 Dec; 30 Suppl 2():168-72. PubMed ID: 19756615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of histopathology to gene expression profiling for the diagnosis of metastatic cancer.
    Kulkarni A; Pillai R; Ezekiel AM; Henner WD; Handorf CR
    Diagn Pathol; 2012 Aug; 7():110. PubMed ID: 22909314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Poorly differentiated carcinoma of unknown primary site: clinical usefulness of immunoperoxidase staining.
    Hainsworth JD; Wright EP; Johnson DH; Davis BW; Greco FA
    J Clin Oncol; 1991 Nov; 9(11):1931-8. PubMed ID: 1941051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integration of genomics and histology revises diagnosis and enables effective therapy of refractory cancer of unknown primary with
    Gröschel S; Bommer M; Hutter B; Budczies J; Bonekamp D; Heining C; Horak P; Fröhlich M; Uhrig S; Hübschmann D; Geörg C; Richter D; Pfarr N; Pfütze K; Wolf S; Schirmacher P; Jäger D; von Kalle C; Brors B; Glimm H; Weichert W; Stenzinger A; Fröhling S
    Cold Spring Harb Mol Case Stud; 2016 Nov; 2(6):a001180. PubMed ID: 27900363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multicenter study directly comparing the diagnostic accuracy of gene expression profiling and immunohistochemistry for primary site identification in metastatic tumors.
    Handorf CR; Kulkarni A; Grenert JP; Weiss LM; Rogers WM; Kim OS; Monzon FA; Halks-Miller M; Anderson GG; Walker MG; Pillai R; Henner WD
    Am J Surg Pathol; 2013 Jul; 37(7):1067-75. PubMed ID: 23648464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A retrospective study of treatment outcomes in patients with carcinoma of unknown primary site and a colorectal cancer molecular profile.
    Hainsworth JD; Schnabel CA; Erlander MG; Haines DW; Greco FA
    Clin Colorectal Cancer; 2012 Jun; 11(2):112-8. PubMed ID: 22000811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A 92-gene cancer classifier predicts the site of origin for neuroendocrine tumors.
    Kerr SE; Schnabel CA; Sullivan PS; Zhang Y; Huang VJ; Erlander MG; Brachtel EF; Dry SM
    Mod Pathol; 2014 Jan; 27(1):44-54. PubMed ID: 23846576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective gene signature study using microRNA to identify the tissue of origin in patients with carcinoma of unknown primary.
    Varadhachary GR; Spector Y; Abbruzzese JL; Rosenwald S; Wang H; Aharonov R; Carlson HR; Cohen D; Karanth S; Macinskas J; Lenzi R; Chajut A; Edmonston TB; Raber MN
    Clin Cancer Res; 2011 Jun; 17(12):4063-70. PubMed ID: 21531815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An expression-based site of origin diagnostic method designed for clinical application to cancer of unknown origin.
    Tothill RW; Kowalczyk A; Rischin D; Bousioutas A; Haviv I; van Laar RK; Waring PM; Zalcberg J; Ward R; Biankin AV; Sutherland RL; Henshall SM; Fong K; Pollack JR; Bowtell DD; Holloway AJ
    Cancer Res; 2005 May; 65(10):4031-40. PubMed ID: 15899792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.